Rolf Teschke | Precision Medicine | Best Academic Researcher Award

Prof. Rolf Teschke | Precision Medicine | Best Academic Researcher Award

Prof. Rolf Teschke | Klinikum Hanau | Germany

Rolf Teschke, M.D., Professor of Medicine, is a distinguished German physician and internationally recognized expert in gastroenterology, hepatology, and the complex mechanisms of hepatotoxicity. Born in Gera, he pursued medical studies at the universities of Munich and Marburg, earning his medical degree and completing his inaugural thesis. His early scientific foundation was shaped in pathology, where his interest in liver injury and toxic mechanisms first took root. A pivotal stage of his career unfolded in New York, where he worked under the mentorship of renowned liver specialist Charles S. Lieber. During this period, he conducted influential biochemical research on alcohol-related liver injury, including solubilizing and isolating the microsomal ethanol-oxidizing system and exploring cytochrome P450–related pathways. This work strengthened his commitment to uncovering the biological foundations of hepatotoxicity and decisively shaped his future research direction. Returning to Germany, Professor Teschke continued to advance academically in gastroenterology, hepatology, and infectious diseases at the Heinrich Heine University of Düsseldorf. He completed his habilitation, received a prestigious university research award, and expanded his clinical and experimental work on alcohol-induced liver damage, hydrocarbon toxicity, and the growing challenge of drug-induced liver injury. As a department director at a major teaching hospital, he further deepened his focus on drug-induced liver injury, contributing significantly to the development and refinement of the RUCAM causality assessment method in collaboration with international experts. His scholarly output is substantial, consisting of more than 250 English-language publications, including books and book chapters. His work has earned 6,890 citations across 4,042 documents, with an h-index of 48, reflecting his strong influence in the global hepatology community. He has served as associate editor of Annals of Hepatology and held editorial roles across numerous leading medical and scientific journals.

Profile; Scopus | Orcid | Research Gate

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Sylvia Mangani | Medical Discoveries | Best Researcher Award

Ms. Sylvia Mangani | Medical Discoveries | Best Researcher Award

Ms. Sylvia Mangani | University of Patras | Greece

Sylvia Mangani is a biochemist–biotechnologist and PhD candidate in Biochemistry at the University of Patras, whose research centers on cancer biology, particularly the influence of the extracellular matrix on tumor growth and regulation through 3D cell culture systems. Her academic journey combines strong foundations in biochemistry and biotechnology (BSc, MSc) with advanced experimental and analytical expertise. Her work integrates a broad range of molecular and cellular biology techniques, including quantitative PCR, Western blotting, immunofluorescence, functional assays, and RNA sequencing, complemented by bioinformatics analysis for gene expression and signaling pathway interpretation. Her research has significantly contributed to understanding how 3D cellular microenvironments influence cancer progression, focusing on breast cancer models. She has authored 12 peer-reviewed publications in recognized international journals, with her work cited over 55 times according to Google Scholar, reflecting growing recognition within the scientific community. Her contributions have also supported award-winning synthetic biology initiatives under the iGEM program and have been presented at national and international scientific conferences. She has established productive collaborations with prominent research institutions in Greece and abroad. Notably, she completed a funded Erasmus+ research placement at the University Hospital of Münster, Germany, under the supervision of Prof. Martin Götte, where she engaged in experimental oncology projects exploring cancer cell behavior and matrix interactions. She has also collaborated with the National and Kapodistrian University of Athens on biochemical and molecular analyses within the Laboratory of Biochemistry, Biotechnology, and Molecular Analysis. A member of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), she actively contributes to the advancement of biochemical and cancer research in Greece and Europe. Her ongoing studies aim to deepen the understanding of tumor–matrix dynamics in breast cancer, offering new insights for therapeutic innovation and cancer model development, positioning her among emerging researchers in molecular oncology.

Profiles: Orcid | Google Scholar | LinkedIn | Research Gate

Featured Publications 

Mangani, S., Piperigkou, Z., Mangani, S., Koletsis, N. E., Koutsakis, C., Mastronikolis, N. S., Franchi, M., & Karamanos, N. K. (2025, August). Principal mechanisms of extracellular matrix‐mediated cell–cell communication in physiological and tumor microenvironments. The FEBS Journal. https://doi.org/10.1111/febs.70207

Mangani, S., Vetoulas, M., Mineschou, K., Spanopoulos, K., Vivanco, M. d. M., Piperigkou, Z., & Karamanos, N. K. (2025, July 15). Design and applications of extracellular matrix scaffolds in tissue engineering and regeneration. Cells, 14(14), 1076. https://doi.org/10.3390/cells14141076

Franchi, M., Masola, V., Onisto, M., Franchi, L., Mangani, S., Zolota, V., Piperigkou, Z., & Karamanos, N. K. (2025, July 7). Ultrastructural changes of the peri-tumoral collagen fibers and fibrils array in different stages of mammary cancer progression. Cells, 14(13), 1037. https://doi.org/10.3390/cells14131037

Karamanos, N. K., Piperigkou, Z., Gourdoupi, C., Mangani, S., & Vivanco, M. d. M. (2025, June 1). Extracellular matrix matters: Matrix-based bioscaffolds in advancing translational cancer research and targeted therapy. American Journal of Physiology-Cell Physiology, 328(6), C1235–C1251. https://doi.org/10.1152/ajpcell.00050.2025

Ciampelli, C., Mangani, S., Nieddu, G., Formato, M., Ioannou, P., Kremmydas, S., Karamanos, N., & Lepedda, A. J. (2025, March). Effects of acidic polysaccharide-enriched extracts from Holothuria tubulosa on two- and three-dimensional invasive breast cancer cell models. Biology, 14(4), 334. https://doi.org/10.3390/biology14040334

Mangani, S., Kremmydas, S., & Karamanos, N. K. (2025, March). Mimicking the complexity of solid tumors: How spheroids could advance cancer preclinical transformative approaches. Cancers, 17(7), 1161. https://doi.org/10.3390/cancers17071161

Haishan Jiang | Medical Discoveries | Innovation in Science Award

Dr. Haishan Jiang | Medical Discoveries | Innovation in Science Award 

Dr. Haishan Jiang, Southern Medical University, China

Dr. Haishan Jiang, Chief Physician and Associate Professor at Southern Medical University’s Nanfang Hospital, is a leading expert in neurology, specializing in myopathy, peripheral neuropathy, and rare neurological diseases. As Deputy Director of the Neurology Department and head of the Myopathy and Peripheral Neuropathy subspecialty, he has pioneered gene therapies for SMA and ALS in South China. His research focuses on motor neuron and mitochondrial diseases, as well as gene therapy for rare conditions. Widely recognized, Dr. Jiang has been honored as the “Good Doctor of Guangzhou” and ranks top nationally in physician recommendations for multiple rare diseases.

Author Profile

ORCID

🧑‍🎓 Early Academic Pursuits

Dr. Haishan Jiang embarked on his medical journey with a deep-rooted commitment to understanding the complexities of the human nervous system. With a Doctor of Medicine degree and solid academic grounding, he demonstrated early on a keen interest in neurology, particularly in the areas of myopathy and peripheral neuropathy. His academic path was marked by diligence, a sharp scientific mind, and a profound dedication to uncovering the underlying mechanisms of rare neurological diseases. As a postgraduate supervisor, Dr. Jiang has also shown a strong passion for nurturing the next generation of medical professionals, sharing his knowledge and guiding their research pursuits with patience and precision.

🩺 Professional Endeavors

Currently serving at Nanfang Hospital of Southern Medical University, Dr. Jiang holds several key positions: Chief Physician, Associate Professor, Deputy Director of the Neurology Department, Director of Teaching, and Head of the Myopathy and Peripheral Neuropathy subspecialty. His clinical expertise spans a wide spectrum of neurological disorders, with a particular emphasis on difficult and rare conditions such as motor neuron disease (ALS), mitochondrial encephalomyopathy, and adult-onset spinal muscular atrophy (SMA). Dr. Jiang’s commitment to clinical excellence has led him to establish and lead the Guangdong Province Myopathy and Peripheral Nerve Specialized Alliance, a network aimed at advancing diagnosis, treatment, and research collaboration. Under his leadership, the department ranks among the top two nationally in terms of annual muscle and nerve biopsy volume, solidifying its reputation as a hub for neuromuscular disease care.

🧬 Contributions and Research Focus

Dr. Jiang’s research interests are firmly rooted in neurogenetic disorders, particularly motor neuron diseases (ALS) and mitochondrial disorders. His work seamlessly blends basic science with clinical application, focusing on understanding disease mechanisms and exploring cutting-edge gene therapy approaches. He has spearheaded some of South China’s most advanced gene therapy trials, including the region’s first gene therapy for adult SMA—the fourth such case in the country—and the first ALS gene therapy clinical trial in South China, also the second nationwide. His pioneering research not only contributes to academic knowledge but also offers hope to patients battling previously untreatable conditions. Through his clinical studies, Dr. Jiang is pushing the frontiers of personalized medicine, bringing precision diagnostics and therapy into the mainstream for rare and complex neurological diseases.

🏅 Accolades and Recognition

Dr. Haishan Jiang’s unwavering dedication to medical science and patient care has earned him widespread acclaim. Notably, he was honored as the sixth “Good Doctor of Guangzhou” and selected as part of the ninth batch of “Outstanding Provincial and Municipal Talents Supporting Xinjiang”, a testament to both his clinical excellence and humanitarian spirit. Furthermore, he was recognized by the Good Doctor Network as an “Annual Good Doctor” for his exceptional service in rare disease diagnosis and treatment. His reputation as a leading clinician is reflected in his top rankings in national physician recommendation lists—first place for 13 diseases, including ALS and mitochondrial encephalomyopathy, and second place for 15 others. These accolades not only highlight his expertise but also the trust he has earned from patients and peers alike.

🌍 Impact and Influence

Dr. Jiang’s work has had a transformative impact on neurology in China, particularly in the realm of rare diseases. By advancing the use of gene therapy and establishing regional alliances, he has created a robust infrastructure for collaboration, research, and clinical care. His contributions have significantly improved diagnostic timelines and therapeutic options for patients who previously faced long diagnostic odysseys and limited treatment possibilities. As a teacher and mentor, Dr. Jiang has shaped the careers of countless postgraduate students and young doctors, many of whom now contribute to clinical neurology and research across the country. His influence extends beyond the clinic to policy and advocacy, where he is a strong voice for the rare disease community.

🔬 Legacy and Future Contributions

Dr. Haishan Jiang stands at the forefront of a new era in neurology, where genomics and personalized medicine are reshaping how we understand and treat complex diseases. His legacy is already evident in the systems he has built, the patients he has helped, and the students he has inspired. Looking ahead, Dr. Jiang aims to further expand gene therapy applications, develop innovative treatment protocols, and foster international collaboration in rare disease research. With his continued focus on combining scientific rigor with compassionate care, Dr. Jiang is set to leave a lasting legacy in Chinese and global neurology. His work is not only rewriting the medical narrative for patients with rare conditions but also paving the way for future breakthroughs in neuroscience.

✍️ Publication Top Notes


📘A Multicenter Study of Hereditary Transthyretin Amyloidosis in China

Author: Xujun Chu; Juan Kang; Jingwen Xu; Haishan Jiang; Zhi‐Ying Wu; Qingping Wang; Wei Li; Jia Li;
Journal: Annals of Neurology
Year:2025

📘Knockdown of OPTN modulates miRNA-125b-5p expression via NF-κB pathways in amyotrophic lateral sclerosis

Author: Jian Qin; Ye He; Weiyi Yu; Zhaoyong Zhang; Xiaodan Chen; Yafang Hu; Haishan Jiang
Journal: Archives of Biochemistry and Biophysics
Year: 2025

📘Clinical features of hereditary transthyretin amyloidosis-polyneuropathy with transthyretin Ala97Ser(p.Ala117Ser) mutation in South Mainland China

Author: Yeli Zhu; Jingxian Fan; Xiying Zhu; Wei Li; Zhaoyong Zhang; Hui Zheng; Zhihua Zhou; Lingchao Meng; Ruxu Zhang; Haishan Jiang
Journal: Orphanet Journal of Rare Diseases
Year: 2025